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Abstract
Background: Postherpetic neuralgia (PHN) is the painful complication of a varicella zoster virus reactivation. We
investigated the systemic and local gene expression of pro- and anti-inflammatory cytokine expression in patients with PHN.
Methods: Thirteen patients with PHN at the torso (Th4-S1) were recruited. Skin punch biopsies were obtained from the
painful and the contralateral painless body area for intraepidermal nerve fiber density (IENFD) and cytokine profiling.
Additionally, blood was withdrawn for systemic cytokine expression and compared to blood values of healthy controls. We
analyzed the gene expression of selected pro- and anti-inflammatory cytokines (tumor necrosis factor-alpha [TNF] and
interleukins [IL]-1b, IL-2, and IL-8).
Results: IENFD was lower in affected skin compared to unaffected skin (p,0.05), while local gene expression of pro- and
anti-inflammatory cytokines did not differ except for two patients who had 7fold higher IL-6 and 10fold higher IL-10 gene
expression in the affected skin compared to the contralateral unaffected skin sample. Also, the systemic expression of
cytokines in patients with PHN and in healthy controls was similar.
Conclusion: While the systemic and local expression of the investigated pro- and anti-inflammatory cytokines was not
different from controls, this may have been influenced by study limitations like the low number of patients and different
disease durations. Furthermore, other cytokines or pain mediators need to be considered.
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Introduction
Postherpetic neuralgia (PHN) is the painful complication of a
varizella zoster virus reactivation. Up to 30% of patients with
acute herpes zoster develop PHN resulting in persistent pain that is
often resistant to analgesic treatment [1,2]. The pathophysiology
of pain in PHN is incompletely understood. High pain intensity
during acute herpes zoster infection is one risk factor [3] and the
question is why. One potential mechanism for the development of
this localized pain syndrome with frequently associated severe
allodynia and sometimes also itch [4] is the influence of algesic
mediators such as pro-inflammatory cytokines, which might
sensitize nociceptors locally.
Cytokines are pleiotropic small proteins that are key players in
the induction and maintenance of neuropathic pain [5]. In several
neuropathic pain conditions such as painful neuropathies, complex
regional pain syndrome or small fiber neuropathy, an imbalance of
systemic or local cytokine profiles has been reported e.g. for pro-
and anti-inflammatory interleukins [6–9]. Although it is unclear if
alterations in cytokine profiles are the cause or the consequence of
neuropathic pain in these disorders, data from animal experiments
give unequivocal evidence for the importance of cytokine
homoeostasis as the basis for physiological pain perception [10].
In PHN, so far, only few and conflicting data on cytokine profiles
are available. One study showed increased interleukin (IL)-8
concentrations in the cerebrospinal fluid of PHN patients [11],
while in another study CSF levels of IL-8, IL-1a, IL-1b, IL-10, and
tumor necrosis factor-alpha (TNF) were not different between
patients with PHN and healthy controls [12]. In turn, long-term
anti-TNF treatment (e.g. in patients with rheumatoid arthritis)
while increasing the overall risk of herpes zoster, seems to reduce
the incidence of PHN [13,14].
Here we investigated if pain in PHN is associated with
alterations in systemic and local cytokine profiles. We hypothe-
sized that patients with PHN have a local and systemic pro-
inflammatory cytokine profile compared to healthy controls and
compared to unaffected skin.
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Methods
Patients and healthy controls
Between 2007 and 2010, 13 patients with PHN localized in the
dermatomes Th4 to S1 of the torso were recruited at the
Departments of Neurology of the Universities of Wu¨rzburg and
Munich, Germany. The group consisted of five men and eight
women with a median age of 68 years (range 36-88). All patients
were seen and examined by a neurologist and the diagnosis was
confirmed. Routine examination included standardized assess-
ment of pain and in addition of depressive symptoms that were
analyzed with the ‘‘Allgemeine Depressionsskala’’ (ADS, German
version of the Centre for Epidemiologic Studies Depression Scale)
[15]. For blood cytokine analysis a control group of eleven healthy
volunteers without infectious disease, history of PHN, or pain at
the time point of blood withdrawal was recruited. The control
group consisted of three men and eight women with a median age
of 61 years (range 37–73). Due to the diversity of the lesion site in
PHN patients we did not perform respective skin biopsies in
healthy controls. Subjects were excluded in case of current
infectious diseases, heavy physical activity or alcohol consumption
the day before. Our study was approved by the Wu¨rzburg and
Munich Medical School Ethics Committees. Study participants
were included after written informed consent was obtained.
Quantitative sensory testing
All patients underwent quantitative sensory testing (QST)
according to the standardized protocol of the DFNS (‘‘Deutscher
Forschungsverbund Neuropathischer Schmerz’’, German Re-
search Network of Neuropathic Pain) [16]. Thermal and
mechanical detection and pain thresholds were determined in
the affected painful area in comparison to a contralateral
unaffected area. In patients with the unaffected area in the back
we also compared individual QST results with published
normative values [17]. Parameters included cold and warm
detection thresholds (CDT, WDT), thermal sensory limen (TSL),
cold and heat pain thresholds (CPT, HPT), mechanical detection
threshold (MDT), mechanical pain threshold (MPT), mechanical
pain sensitivity (MPS), vibration detection threshold (VDT) and
pressure pain threshold (PPT). Based on the log transformed raw
values for each item a z-score sensory profile was calculated. The
presence of dynamic mechanical allodynia was determined by
gentile brush of the respective area.
Blood withdrawal and RNA extraction
Five ml of venous whole blood was collected between 8 and 9
a.m. in PAXgene Blood RNA Tubes (PreAnalytics, BD, Hom-
brechtikon, Switzerland) after over-night fasting from all study
participants. Blood samples were kept at room temperature for
two hours before storage at 280uC. For RNA extraction the
PAXgene Blood RNA MDx Kit (BD, Hombrechtikon, Switzer-
land) was used.
Skin punch biopsy
A 5-mm skin punch biopsy (Stiefel GmbH, Offenbach,
Germany) was taken in local anesthesia from the affected painful
and a corresponding contralateral unaffected site of patients with
PHN as previously described [9]. Each skin specimen was divided
into two pieces: one piece was incubated in 4% paraformaldehyde
(PFA) for two hours at +4uC and was further processed for protein
gene product 9.5 (PGP 9.5) staining; one piece was put in
RNAlater RNA Stabilization Reagent (Qiagen, Hilden, Germany)
and stored at -80uC before RNA extraction.
RNA extraction from skin samples
After thawing, the skin samples were homogenized in 1 ml
TRIzol reagent (Invitrogen, Karlsruhe, Germany) and homoge-
nized with an Ultraturrax homogenizer (Polytron PT 1600E,
Kinematica, Luzern, Switzerland). After adding 200 ml of chloro-
form the samples were incubated at 25uC for 3 min and after spin
down (12.000 g615 min64uC) the supernatant was mixed with
500 ml isopropanole. After incubation (25uC for 10 min) and
another spin down (12.000 g610 min64uC) the pellet was washed
with ethanol 75%. After another centrifugation step
(7500 g65 min64uC) the samples were air-dried on ice for
5 min and the pellet was dissolved in water treated with
diethylpyrocarbonate. Then the samples were incubated in a
water bath at 55uC for 10 min.
Reverse transcription PCR
For reverse transcription of 750 ng of the extracted RNA,
TaqMan Reverse Transcription Reagents (Applied Biosystems,
Darmstadt, Germany) were used. The reaction was carried out at
a total volume of 100 ml. Five ml of random hexameres were added
to 750 ng RNA and the mixture was filled up with RNase free
water to an end volume of 37.8 ml. After heat denaturation (85uC,
3 min), 2 ml of Oligo-dt, 10 ml 106 PCR-buffer, 6.25 ml Multi-
scribe reverse transcriptase, 2 ml RNase inhibitor, 22 ml MgCl2,
and 20 ml dNTPs were added. The PCR cycler conditions were as
follows: annealing at 25uC for 10 min, reverse transcription at
48uC for 60 min and enzyme inactivation at 95uC for 5 min.
Quantitative real-time PCR
Five ml of cDNA were used for quantitative real-time PCR
(qRT-PCR), which was performed in the GeneAmp 7700
sequence detection system (Applied Biosystems, Darmstadt,
Germany) capable of fluorescence using TaqMan Universal
Master Mix (Applied Biosystems, Darmstadt, Germany). Gene
specific oligonucleotide primers and probes for human in IL-1b,
IL-6, IL-8, tumor necrosis factor-alpha (TNF), and IL-10 as well as
the endogenous control 18sRNA were obtained as TaqMan
Assays (Applied Biosystems, Darmstadt, Germany; see Table 1 for
Assay-ID). The reaction contained 12.5 ml TaqMan Master Mix
and 1.25 ml of the specific primer in an end volume of 25 ml. The
cycler conditions were as follows: incubation for 2 min at 50uC
followed by another incubation step at 95uC for 10 min,
afterwards 45 cycles with 15 sec at 95uC and 1 min at 60uC. In
order to guarantee primer specificity and to exclude genomic
contamination, negative controls without cDNA template were
run on each qRT-PCR well plate. All samples were measured as
triplicates, while the 18s-values were measured as duplicates.
For gene expression analysis in blood samples each qRT-PCR
reaction plate contained a calibrator sample, which was the blood
sample of the control person whose threshold cyclus (Ct)-values
(i.e. qRT-PCR cyclus at which a significant signal was detected)
were next to the calculated mean of all control blood samples
specific for each primer. The evaluation of the obtained data was
performed with the comparative DDCt-method and data of PHN
patients were compared with healthy controls. For gene expression
analysis in skin samples the gene expression in the affected skin
sample of the individual patients were compared with the gene
expression in the respective unaffected skin sample. Again the
DDCt-method was used.
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PGP 9.5 immunofluorescence for intraepidermal nerve
fiber density
After fixation in 4% PFA (pH 7.4) for two hours at 4uC, skin
samples were washed in 0.1 M phosphate buffer and transferred to
10% sucrose over-night. Afterwards tissue was embedded in Tissue
Tek, frozen in 2-methylbutane cooled in liquid nitrogen and was
stored at 280uC before further processing. Fifty-mm sections were
cut with a microtome and were stained with rabbit polyclonal
antibodies to human PGP 9.5 (Ultraclone, UK, 1:800; primary
antibody) and goat anti-rabbit IgG labeled with cyanine 3.18
fluorescent probe (Amersham, USA, 1:100; Cy3, secondary
antibody). A microscope (Axiophot 2, Zeiss, Jena, Germany) with
a CCD camera (Visitron Systems, Tuchheim, Germany) and
SPOT advanced software (Windows Version 4.5) were used for
visualization. Nerve fibers were counted using a 406 objective
according to standard criteria [18]. The average intraepidermal
nerve fiber density (IENFD) per mm of epidermal length was
calculated following international standards [19].
Assessment of inflammatory cells in the skin
We used 10 mm skin sections to visualize T-cells (CD-3, 1:200,
Abcam, Germany), macrophages (CD-68, 1:3000, Abcam,
Germany), and Langerhans cells (CD-1a, 1:500, Beckman
Coulter, Krefeld, Germany). Stains were performed using a
standard immunohistochemistry protocol (ABC kit, Vector,
Germany) with diaminobenzidine as chromogen and hemalaun
as a counterstain. Cells were assessed semiquantitatively by an
investigator blinded to the diagnosis with regard to cell density:
0 = no cells; 1 = single cells; 2 = several cells; 3 = dense cell
infiltrates.
Statistical analysis
Data were analyzed using IBM SPSS software (Version 21,
Ehningen, Germany). qRT-PCR data did not display normal
distribution in the Shapiro-Wilk-test, thus we used the Mann-
Whitney-U-test for comparison of independent groups; the QST
data were normally distributed and the t-test for independent
groups was applied. We used the Levene test to check for equality
in variance. Statistical significance was assumed at p,0.05.
Results
Characteristics of study population
Table 1 gives baseline data of the PHN patients. Seven patients
were on analgesic medication with pregabalin (n = 5), amitripty-
line, carbamazepine, duloxetine, fentanyl, flupirtine, lidocaine,
and tilidine (n = 1 each) as monotherapy or in different combina-
tions. The median duration of pain was four years (four months to
20 years) and the median current pain intensity on a numeric
rating scale (0 = no pain, 10=worst pain imaginable) was 7 (3–8).
No correlation was found between depressive symptoms and pain.
Patients with PHN have hypoesthesia for warm and
touch
QST showed that warm detection (p,0.05) and detection of
mechanical stimulation (p,0.05) were impaired in the affected
skin area compared the unaffected side in patients with PHN
(Fig. 1). Dynamic mechanical allodynia was present in 6/13 (46%)
patients in the affected area. QST parameters did not correlate
with pain. Also, QST results of the unaffected contralateral area at
Figure 1. Sensory profile of patients with postherpetic neuralgia (PHN) assessed with quantitative sensory testing (QST), affected
skin is compared to unaffected skin (zero line). In affected skin, patients showed elevated detection thresholds for warm and for tactile stimuli
(*p,0.05). Abbreviations: CDT: cold detection threshold; CPT: cold pain threshold; HPT: warm pain threshold; MDT: mechanical detection threshold;
MPS: mechanical pain sensitivity; MPT: mechanical pain threshold; PHS: paradoxical heat sensation; PPT: pressure pain threshold; TSL: thermal sensory
limen; VDT: vibration detection threshold; WDT: warm detection threshold.
doi:10.1371/journal.pone.0105269.g001
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the back (n = 5 patients, see Table 1) were not different from
published normative values.
Cutaneous innervation is reduced in affected skin
In 11/13 (85%) patients with PHN the IENFD was lower in skin
of the affected site compared to the unaffected contralateral side
(p,0.05; Fig. 2). The median IENFD in affected skin was 5 fibers/
mm (0–21 fibers/mm) and in unaffected skin 15 fibers/mm (5–29
fibers/mm). IENFD did not correlate with pain.
No inflammatory infiltrates are present in affected an
unaffected skin
The semiquantitative assessment of dermal T-cells and macro-
phages and epidermal Langerhans cells did not reveal cellular
infiltrates in the affected and unaffected skin (data not shown).
Systemic cytokine gene expression does not differ from
controls
Systemic gene expression of the pro- and anti-inflammatory
cytokines IL-1b, IL-6, IL-8, TNF, and IL-10 did not differ
between patients with PHN and healthy controls (Fig. 3). Also, no
difference was found when comparing patients with and without
current analgesic medication.
Local cytokine gene expression does not differ between
affected and unaffected sides
Local gene expression of the investigated markers was similar in
affected and unaffected skin of patients with PHN (Fig. 4) for all
investigated cytokines irrespective of current analgesic treatment.
Also, patients with and without allodynia did not differ in cytokine
expression patterns. In two patients IL-6 and IL-10 gene
expression was very high in the affected skin (7fold higher IL-6
expression and 10fold higher IL-10 expression compared to
unaffected skin area; patients #5 and #9 in Table 2).
Discussion
PHN is associated with severe localized pain of incompletely
understood pathophysiology. We confirm the reduction of IENFD
in affected skin compared to unaffected skin [20,21], however, in
contrast to our hypothesis, we did not observe a pro-inflammatory
cytokine profile in PHN patients. No changes were found in
Figure 2. Boxplots show the intraepidermal nerve fiber density (IENFD) in affected versus unaffected skin of patients with
postherpetic neuralgia (PHN). In affected skin IENFD is lower than in corresponding (contralateral) unaffected skin (*p,0.05). The horizontal black
line in the box marks the median value.
doi:10.1371/journal.pone.0105269.g002
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systemic and local cytokine gene expression profiles of patients
with PHN compared to healthy controls and between affected and
unaffected skin.
Cytokine measurements in PHN
Cytokines play a crucial role in neuropathic pain induction and
maintenance [5,10]. This has been shown in a large number of
different animal models and also in several human neuropathic
pain disorders. Especially in localized pain states such as small
fiber neuropathy and complex regional pain syndrome elevated
cytokine levels have been reported [9,22]. A local increase in
algesic pro-inflammatory cytokines was therefore assumed in
PHN, however, it had not been studied so far.
In patients both with acute herpes zoster and PHN, cytokine
levels have been investigated in the cerebrospinal fluid (CSF)
[11,12] and in the blood [23] giving conflicting results. In the
study by Kotani et al. control subjects had an IL-8 concentration
of 18 mg/L (7 to 24 mg/L) in the CSF compared to 81 mg/L (57 to
380 mg/L) in patients with herpes zoster during rash and after rash
healing (44 mg/L, 28 to 101 mg/L). An initially increased IL-8
CSF level was found to be an independent predictor of PHN [11].
In another study IL-1a, IL-1b, IL-10, TNF, MIP-1a, and
fractalkine levels were below the detection limit in the majority
of the investigated 25 PHN patients similar to controls and IL-8
levels were not different between groups [12]. This discrepancy
might be explained by the fact that in the study by Rijsdijk et al. a
PHN cohort had been examined that had a median pain duration
of 24 months, thus IL-8 levels may have normalized in the
meantime. Similarly, our patients had a median duration of pain
of four years, and we cannot preclude that there might have been
differences in cytokine expression earlier on. However, cytokine
expression in our cohort did not correlate with disease duration
(data not shown).
Zhu et al. showed that in serum samples of patients who already
suffered from pain in the acute phase of herpes zoster IL-1b, IL-6,
IL-8, TNF, and IL-10 protein levels were higher compared to
healthy controls. In particular, IL-6 protein levels were higher in
ten of the investigated 49 patients who later developed PHN and
positively correlated with pain severity [23]. The observational
period of this study was six months.
The assumption that changes in cytokine expression levels may
be of pathophysiological importance in PHN induction and
maintenance is supported by observations in patients that received
anti-cytokine medication. In a retrospective analysis of patients
with rheumatoid arthritis on anti-TNF treatment the number of
PHN after herpes zoster was remarkably lower (only two cases out
Figure 3. Boxplots illustrate the systemic (blood) relative gene expression of the pro- and anti-inflammatory cytokines interleukin-
1b (IL-1b), IL-6, IL-8, tumor necrosis factor-alpha (TNF), and IL-10 comparing patients with postherpetic neuralgia (PHN) and healthy
controls. No intergroup difference was found.
doi:10.1371/journal.pone.0105269.g003
Postherpetic Neuralgia and Cytokines
PLOS ONE | www.plosone.org 6 August 2014 | Volume 9 | Issue 8 | e105269
of 206) compared to data of the general population [13]. In
contrast, the development of severe PHN was reported after
inadvertent infliximab administration [24]. In a prospective study
assessing the risk of herpes zoster in more than 5000 patients with
rheumatoid arthritis treated with anti-TNF drugs, 86 episodes of
herpes zoster were recorded in 82 patients; in two of these patients
PHN occurred [14].
In another study Zak-Prelich assessed serum cytokine levels and
different subtypes of skin lymphocytes in patients with herpes
zoster who did and did not develop PHN [25]. Interestingly, a
reduced number of cellular infiltrates was found at the lesion sites
of herpes zoster patients that developed PHN compared to those
who did no without association with systemic cytokine levels. The
authors suggested that an impaired immune response upon zoster
infection resulted in an impaired containment of infection and
more damage of the dermatome as the basis for neuralgia. Here,
we did not find infiltrates of T-cells and macrophages in affected
skin of PHN patients compared to unaffected skin, which may be
due to the different duration of disease in our study until biopsy,
while in the study by Zak-Prelich et al. patients were seen at
standardized time points (within the first ten days of disease and
one week later).
Treatment of PHN
Since part of the pathology in PHN has been assumed to be
located in the skin itself, also surgical excision of the lesioned skin
has been tried. However, this approach did not lead to sustained
pain relief [26], which indicates that the assumed pathology might
be located upstream the pain pathway such as in dorsal root
ganglia neurons. Interestingly, a recent case report described the
analgesic effect of local laser therapy of the skin over a period of 13
months in a 73 year old women who had been suffering from PHN
for 15 years [27]. The author suggested that the reducing effect of
laser on local cytokine expression might be the underlying
mechanism of this observation, however, cytokine levels were
not investigated. In another case report the analgesic effect of anti-
IL-2 that lasted throughout the three years of the follow-up period
was described in a patient with PHN [28], but again cytokine
levels were not measured before and after treatment.
Affected skin is denervated, unaffected skin is spared
Histological assessment of skin samples also revealed denerva-
tion of affected skin compared to unaffected contralateral skin in
patients with PHN. This finding is in accordance with pervious
findings. Petersen et al. reported a 40% reduction in painful skin
compared to painless skin [21]. Similar results were found in the
study of Buonocore et al. [20]. In accordance with these studies we
also did not find a correlation between IENFD and the presence or
absence of allodynia. As outlined in Table 1, IENFD of patients
with and without allodynia ranged from normal to complete
denervation. Also, no correlation was found between IENFD and
patients’ current pain intensity. Further studies are needed to
decipher the underlying mechanisms that may range from
Figure 4. Scatter plots illustrate the local (skin) relative gene expression of the pro-inflammatory cytokines interleukin-1b (IL-1b),
IL-6, IL-9, tumor necrosis factor-alpha (TNF) and the anti-inflammatory cytokine IL-10 in affected skin of patients with postherpetic
neuralgia (PHN) compared to unaffected (contralateral) skin that is calibrated to a relative gene expression of 1.
doi:10.1371/journal.pone.0105269.g004
Table 2. Primers and Assay-IDs of the TaqMan assays used.
Primer Assay-ID
IL-1b Hs00174097_m1
IL-6 Hs00174131_m1
IL-8 Hs00174103_m1
TNF Hs00174128_m1
IL-10 Hs00174086_m1
Abbreviations:
IL: interleukin; TNF: tumor necrosis factor-alpha.
doi:10.1371/journal.pone.0105269.t002
Postherpetic Neuralgia and Cytokines
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hyperexcitable remaining nerve fibers causing allodyina while
IENFD is normal, to hyperactive dorsal root ganglion neurons
independent of peripheral nerve fiber density.
Limitations
The major limitation of our study is the relatively low number of
patients and controls. Although we were recruiting at two centers,
only 13 patients with PHN were seen during the study period of
three years. This may be due to the fact that in the majority of
cases patients with PHN are not hospitalized but treated as
outpatients. Our patient group was inhomogeneous with regard to
disease duration, which may have influenced our results such that
we missed early changes in cytokine gene expression. We cannot
exclude influence of current analgesic medication on the study
results since the study cohort was small and those patients on
analgesic medication used drugs from different pharmaceutical
groups. We focused on cytokines as major algesic mediators, and
due to limitations in bio-samples only a limited number of targets
could be investigated. Also, no protein measurements were
possible. Besides cytokines the assessment of further algesic
mediators (e.g. chemokines, opioid receptors, neurotrophic factors)
would have been desirable.
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